ArticleAnnals of neurology2012
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
Article in Annals of neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review.Molecules (Basel, Switzerland) · 2017Pooled it
- Interactions between daily sleep-wake rhythms, γ-secretase, and amyloid-β peptide pathology point to complex underlying relationships.Biochimica et biophysica acta. Molecular basis of disease · 2025Article
- The amyloid-β peptide: Guilty as charged?Biochimica et biophysica acta. Molecular basis of disease · 2024Article
- Biomarkers and Alzheimer's disease: a bibliometric analysis.Frontiers in aging neuroscience · 2024Review
- Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease.Neurology · 2019Article
- Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.Alzheimer's & dementia (Amsterdam, Netherlands) · 2017Article
- Amyloid Imaging: Poised for Integration into Medical Practice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Molecular and cellular pathophysiology of preclinical Alzheimer's disease.Behavioural brain research · 2016Review
- What amyloid ligands can tell us about molecular polymorphism and disease.Neurobiology of aging · 2016Review
- The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.Molecular neurobiology · 2016Review
- Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease.Neurobiology of aging · 2015Article
- Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.Brain : a journal of neurology · 2015Article
- The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.NeuroImage · 2015Article
- Obesity and diabetes cause cognitive dysfunction in the absence of accelerated β-amyloid deposition in a novel murine model of mixed or vascular dementia.Acta neuropathologica communications · 2014Article
- Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer's disease brain and correlates with neurofibrillary tangle pathology.Journal of Alzheimer's disease : JAD · 2014Article
- Cerebral amyloid PET imaging in Alzheimer's disease.Acta neuropathologica · 2013Review
- Is Alzheimer's disease a homogeneous disease entity?Journal of neural transmission (Vienna, Austria : 1996) · 2013Article
- Prolonged diet induced obesity has minimal effects towards brain pathology in mouse model of cerebral amyloid angiopathy: implications for studying obesity-brain interactions in mice.Biochimica et biophysica acta · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveDeposition of the amyloid-β (Aβ) peptide in neuritic plaques is a requirement for the diagnosis of Alzheimer disease (AD). Although the continued development of in vivo imaging agents such as Pittsburgh compound B (PiB) is promising, the diagnosis of AD is still challenging. This can be partially attributed to our lack of a detailed understanding of the interrelationship between the various pools and species of Aβ and other common indices of AD pathology. We hypothesized that recent advances in our ability to accurately measure Aβ postmortem (for example, using PiB), could form the basis of a simple means to deliver an accurate AD diagnosis.
methodsWe conducted a comprehensive analysis of the amount of Aβ40 and Aβ42 in increasingly insoluble fractions, oligomeric Aβ, and fibrillar Aβ (as defined by PiB binding), as well as plaques (diffuse and neuritic), and neurofibrillary tangles in autopsy specimens from age-matched, cognitively normal controls (n = 23) and AD (n = 22) cases, across multiple brain regions.
resultsBoth PiB binding and the amount of sodium dodecyl sulfate (SDS)-soluble Aβ were able to predict disease status; however, SDS-soluble Aβ was a better measure. Oligomeric Aβ was not a predictor of disease status. PiB binding was strongly related to plaque count, although diffuse plaques were a stronger correlate than neuritic plaques.
interpretationAlthough postmortem PiB binding was somewhat useful in distinguishing AD from control cases, SDS-soluble Aβ measured by standard immunoassay was substantially better. These findings have important implications for the development of imaging-based biomarkers of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.